FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2968222794> ?p ?o ?g. }

• W2968222794 abstract "6615 Background: ATRA administration in suspected APL patients (sAPL) is thought to impact early death rate (EDR) (Tallman and Manji, Blood Cells Mol Dis. 2011). Delay in ATRA therapy at specialized centers was associated with EDR (Altman et al Blood 2011). EDR within this study was significantly lower compared to the SEER database (12% vs 17.3%) and hence may not reflect overall delay in ATRA therapy. We determined time to ATRA therapy in sAPL, and fraction of sAPL that did not have disease. Methods: Retrospective analysis of patients that received ATRA for newly diagnosed s APL between 01/01/98-12/31/11 at Albany Medical Center. Time to hematologist evaluation, ATRA ordered and administered, and mortality data was collected from cancer registry, medical record, and chemo-pharmacy database. Results: A total of 39 patients with newly diagnosed sAPL were administered ATRA (46% male, mean age 50y). APL diagnosis: 29/39 (75%) true APL (APL); 9/10 ATRA-treated non-APL (A-nAPL); and one patient for whom cytogenetic data unavailable. EDR amongst APL was 5/29 (17%) compared to 2/9 (22%) within A-nAPL. Time variables were compared between APL patients that died early (<30d) to those that survived 30 days, and included: time to hematologist response (0.9d vs. 0.4d); time to ATRA ordered (2.9d vs. 2.0d); time to ATRA administered (3.4d v. 2.2d); and time elapsed between hematologist response to ATRA administered (2.5d v. 1.9d), respectively. Cryoprecipitate was administered to 1/5 (20%) patients who expired within 30d compared to 10/23 (43%) who survived. Overall mortality for APL was 9/29 (31%) compared to 4/9 (44%) for A-nAPL group. Compared to recent reports, time to ATRA administration in our institution was later (2.0d vs. 2.4d). Conclusions: Our data indicate that APL patients who survived 30d received ATRA early. EDR at our institution is comparable to that reported by SEER database and may be attributed to delay in ATRA administration. Higher fraction of patients that survived 30d received cryoprecipitate. Hence aggressive blood product support may contribute to improved survival. Timing at which these products were administered is currently being evaluated." @default.
• W2968222794 created "2019-08-22" @default.
• W2968222794 creator A5016201761 @default.
• W2968222794 creator A5021028061 @default.
• W2968222794 creator A5058716554 @default.
• W2968222794 creator A5079145901 @default.
• W2968222794 date "2012-05-20" @default.
• W2968222794 modified "2023-09-27" @default.
• W2968222794 title "Time to ATRA in suspected newly diagnosed acute promyelocytic leukemia and association with early death rate at a non-cancer center institution: Are we meeting the target?" @default.
• W2968222794 doi "https://doi.org/10.1200/jco.2012.30.15_suppl.6615" @default.
• W2968222794 hasPublicationYear "2012" @default.
• W2968222794 type Work @default.
• W2968222794 sameAs 2968222794 @default.
• W2968222794 citedByCount "0" @default.
• W2968222794 crossrefType "journal-article" @default.
• W2968222794 hasAuthorship W2968222794A5016201761 @default.
• W2968222794 hasAuthorship W2968222794A5021028061 @default.
• W2968222794 hasAuthorship W2968222794A5058716554 @default.
• W2968222794 hasAuthorship W2968222794A5079145901 @default.
• W2968222794 hasConcept C104317684 @default.
• W2968222794 hasConcept C121608353 @default.
• W2968222794 hasConcept C126322002 @default.
• W2968222794 hasConcept C143998085 @default.
• W2968222794 hasConcept C179755657 @default.
• W2968222794 hasConcept C185592680 @default.
• W2968222794 hasConcept C2776601000 @default.
• W2968222794 hasConcept C2778461978 @default.
• W2968222794 hasConcept C2781121885 @default.
• W2968222794 hasConcept C55493867 @default.
• W2968222794 hasConcept C71924100 @default.
• W2968222794 hasConceptScore W2968222794C104317684 @default.
• W2968222794 hasConceptScore W2968222794C121608353 @default.
• W2968222794 hasConceptScore W2968222794C126322002 @default.
• W2968222794 hasConceptScore W2968222794C143998085 @default.
• W2968222794 hasConceptScore W2968222794C179755657 @default.
• W2968222794 hasConceptScore W2968222794C185592680 @default.
• W2968222794 hasConceptScore W2968222794C2776601000 @default.
• W2968222794 hasConceptScore W2968222794C2778461978 @default.
• W2968222794 hasConceptScore W2968222794C2781121885 @default.
• W2968222794 hasConceptScore W2968222794C55493867 @default.
• W2968222794 hasConceptScore W2968222794C71924100 @default.
• W2968222794 hasLocation W29682227941 @default.
• W2968222794 hasOpenAccess W2968222794 @default.
• W2968222794 hasPrimaryLocation W29682227941 @default.
• W2968222794 hasRelatedWork W1989678859 @default.
• W2968222794 hasRelatedWork W1999826261 @default.
• W2968222794 hasRelatedWork W2009643046 @default.
• W2968222794 hasRelatedWork W2038644330 @default.
• W2968222794 hasRelatedWork W2042649741 @default.
• W2968222794 hasRelatedWork W2064671776 @default.
• W2968222794 hasRelatedWork W2073715863 @default.
• W2968222794 hasRelatedWork W2081966550 @default.
• W2968222794 hasRelatedWork W2086720502 @default.
• W2968222794 hasRelatedWork W2173574404 @default.
• W2968222794 hasRelatedWork W2548123865 @default.
• W2968222794 hasRelatedWork W2577142201 @default.
• W2968222794 hasRelatedWork W2600261757 @default.
• W2968222794 hasRelatedWork W2610902480 @default.
• W2968222794 hasRelatedWork W2810937432 @default.
• W2968222794 hasRelatedWork W3011052445 @default.
• W2968222794 hasRelatedWork W3019187839 @default.
• W2968222794 hasRelatedWork W3032085027 @default.
• W2968222794 hasRelatedWork W3184779053 @default.
• W2968222794 hasRelatedWork W2336761585 @default.
• W2968222794 isParatext "false" @default.
• W2968222794 isRetracted "false" @default.
• W2968222794 magId "2968222794" @default.
• W2968222794 workType "article" @default.